Millennium Management LLC Acquires New Shares in Cardlytics, Inc. (NASDAQ:CDLX)

Millennium Management LLC acquired a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 144,238 shares of the company's stock, valued at approximately $535,000. Millennium Management LLC owned about 0.28% of Cardlytics at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Mirabella Financial Services LLP purchased a new stake in shares of Cardlytics during the fourth quarter valued at $4,285,000. D. E. Shaw & Co. Inc. lifted its holdings in Cardlytics by 97.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company's stock valued at $4,198,000 after acquiring an additional 558,235 shares during the period. Geode Capital Management LLC lifted its holdings in Cardlytics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,060,739 shares of the company's stock valued at $3,936,000 after acquiring an additional 7,561 shares during the period. RBF Capital LLC lifted its holdings in Cardlytics by 64.7% in the fourth quarter. RBF Capital LLC now owns 803,763 shares of the company's stock valued at $2,982,000 after acquiring an additional 315,635 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Cardlytics by 3.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 402,552 shares of the company's stock valued at $1,493,000 after acquiring an additional 12,209 shares during the period. 68.10% of the stock is owned by hedge funds and other institutional investors.

Cardlytics Stock Up 6.5%

NASDAQ CDLX opened at $1.79 on Monday. The stock's 50-day moving average price is $1.71 and its 200-day moving average price is $2.66. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 52 week low of $1.22 and a 52 week high of $9.78. The company has a market capitalization of $93.98 million, a P/E ratio of -0.29 and a beta of 1.25.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CDLX. Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a report on Thursday, March 13th. Evercore ISI lowered their target price on Cardlytics from $4.00 to $3.00 and set an "in-line" rating on the stock in a report on Thursday, March 13th. Finally, Lake Street Capital lowered their target price on Cardlytics from $3.00 to $2.50 and set a "hold" rating on the stock in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Cardlytics has a consensus rating of "Hold" and an average target price of $5.20.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.